FOR IMMEDIATE RELEASE
July 2025
Biotech Leader Dan Browne Joins Board of Directors at the Lieber Institute for Brain Development
Baltimore, MD — The Lieber Institute for Brain Development (LIBD), an independent nonprofit research institute dedicated to understanding the human brain and developing new treatments for mental illness, is pleased to announce the appointment of Dan Browne to its Board of Directors. Mr. Browne brings more than 30 years of experience as a visionary biotech leader and entrepreneur in the life sciences industry.
Mr. Browne is currently the CEO of Tasman Therapeutics, a clinical-stage pharmaceutical company pioneering novel therapies for treatment-resistant depreDssion. He has a track record of building transformative biopharma companies. Mr. Browne previously co-founded and led Revance Therapeutics (now Revance, Inc.), where he guided the company to IPO and oversaw the development of the FDA-approved long-acting neuromodulator Daxxify™. Over the years he’s raised more than $900 million in private and public capital. He currently serves on the Board of Galderma Group AG, the world’s largest pure-play dermatology company.
“Dan Browne’s deep knowledge of drug discovery and development, combined with his business acumen and passion for mental brain health, makes him an extraordinary addition to our Board,” said Geoffrey Simon, Chair of the Lieber Institute Board. “His leadership will help accelerate our mission to develop and deliver new treatments for people affected by mental illness and age-related diseases.”
Mr. Browne joins the Lieber Institute at a pivotal time as the organization rapidly expands its AI-driven drug discovery platform and deepens its partnerships with industry leaders, including new collaborations with Blackbird Laboratories, ThirdRock Ventures and Amazon Web Services. He will provide strategic insight as the Institute advances drug programs targeting schizophrenia, bipolar disorder, age-related brain diseases and more.
“As someone who has spent his career developing breakthrough treatments, I’m deeply inspired by the Lieber Institute’s singular mission,” said Dan Browne. “The combination of its world-class brain data research, cutting-edge AI platforms, and unwavering commitment to the people it serves makes this one of the most important and promising organizations in neuroscience today.”
A longtime advocate for innovation in mental health care, Mr. Browne has led the development of novel treatments that aim to improve access, speed of relief, and overall outcomes for patients facing the most difficult-to-treat conditions.
“Dan’s strategic insight and operational excellence are exactly what we need as we grow our impact,” said Dr. Daniel R. Weinberger, CEO and Director of the Lieber Institute. “But what sets Dan apart is his genuine passion for people and his belief in the power of science to heal. We are proud to welcome him to our leadership team.”
About the Lieber Institute for Brain Development (LIBD)
The mission of the Lieber Institute for Brain Development and the Maltz Research Laboratories is to translate the understanding of basic genetic and molecular mechanisms of schizophrenia and related developmental brain disorders into clinical advances that change the lives of affected individuals. LIBD is an independent, not-for-profit 501(c)(3) organization and a Maryland tax-exempt medical research institute affiliated with the Johns Hopkins University School of Medicine. The Lieber Institute’s brain repository of more than 5,000 human brains is the largest collection of postmortem brains for the study of neuropsychiatric disorders worldwide.
###
Media Contact: Geoff DeLizzio, media@libd.org